Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) have been given an average rating of “Moderate Buy” by the five ratings firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $7.40.

Several research firms recently weighed in on ATNM. Stephens reissued an “overweight” rating and set a $5.00 price objective on shares of Actinium Pharmaceuticals in a research note on Tuesday, November 19th. HC Wainwright reissued a “buy” rating and issued a $4.00 price target on shares of Actinium Pharmaceuticals in a report on Friday, November 15th. Finally, StockNews.com cut shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, November 11th.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ATNM. Rhumbline Advisers grew its stake in shares of Actinium Pharmaceuticals by 23.4% in the second quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock valued at $293,000 after buying an additional 7,525 shares in the last quarter. The Manufacturers Life Insurance Company bought a new position in shares of Actinium Pharmaceuticals in the 2nd quarter valued at about $92,000. Renaissance Technologies LLC acquired a new position in shares of Actinium Pharmaceuticals during the 2nd quarter worth about $142,000. Interchange Capital Partners LLC bought a new stake in shares of Actinium Pharmaceuticals in the 3rd quarter valued at about $37,000. Finally, Geode Capital Management LLC lifted its stake in Actinium Pharmaceuticals by 3.0% in the 3rd quarter. Geode Capital Management LLC now owns 686,153 shares of the company’s stock valued at $1,290,000 after purchasing an additional 19,843 shares during the last quarter. 27.50% of the stock is currently owned by institutional investors.

Actinium Pharmaceuticals Trading Down 0.8 %

Shares of ATNM opened at $1.22 on Friday. The stock has a market cap of $38.06 million, a P/E ratio of -0.88 and a beta of 0.12. Actinium Pharmaceuticals has a 1 year low of $1.10 and a 1 year high of $10.24. The stock’s 50-day moving average price is $1.30 and its two-hundred day moving average price is $2.15.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).